Indaco Venture Partners

Iama Therapeutics is focused on neuroscience drug discovery, aiming to develop innovative medicines for children with brain disorders. The company specializes in creating novel therapeutics designed to address neurological conditions such as Down syndrome and autism spectrum disorders. Their treatments target learning and memory difficulties, as well as behavioral challenges commonly associated with these conditions. In addition to developing effective drug solutions, Iama Therapeutics is dedicated to supporting families impacted by these disorders, striving to improve the quality of life for both patients and their caregivers.

CamGraPhIC is a developer of advanced graphene photonics technology aimed at enhancing optical telecommunications, particularly in 5G and data center environments. The company focuses on creating electro-optical engines that meet the increasing demand for data traffic while offering high data rates, low costs, and low power consumption. Their technology is compatible with various photonic materials, including silicon and silicon nitride, and can be integrated through scalable wafer-level processes. This capability allows for the production of next-generation optical transceivers, enabling clients to effectively utilize the bandwidth necessary for emerging digital applications such as cloud services and the Internet of Things.

Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

Easy Rain i.S.p.A. is an Italian company founded in 2013, based in Milan, that specializes in enhancing vehicle safety through innovative technology. It has developed a patented active safety system that addresses the hydroplaning phenomenon, which occurs when vehicles lose traction on wet roads due to a layer of water. This issue contributes to millions of accidents annually and poses significant challenges for autonomous driving technologies. Easy Rain’s system prevents excessive water from contacting the tires, thereby improving traction and overall vehicle performance in wet conditions. The company holds extensive patent coverage for its technology and offers solutions that can integrate with remote detection and vision systems to further enhance safety and efficiency for both conventional and electric vehicles.

TES Pharma is a research-based biopharmaceutical company focusses on delivering first in class preclinical candidates that unlock the potential of novel therapeutic targets and mechanisms.

D-Orbit S.r.l. is an Italian New Space company founded in 2011 and headquartered in Sesto Fiorentino, Italy. The company specializes in providing solutions for satellite design, development, launch, commissioning, and decommissioning, with a focus on enabling the safe disposal of artificial satellites to mitigate space debris. D-Orbit offers a range of services, including last-mile delivery of satellites, orbital transportation, and space logistics, aimed at optimizing operations both in orbit and on the ground. By streamlining all phases of a satellite mission, D-Orbit enhances spacecraft design, reliability, and resource utilization while reducing operational costs. The company operates with a commitment to social benefit and environmental sustainability, catering to the needs of satellite owners and operators in a rapidly evolving space marketplace. With approximately 35 employees, D-Orbit also has subsidiaries in Washington, DC, and Lisbon, Portugal.

Genespire is a biotechnology company dedicated to advancing gene therapies for individuals suffering from genetic disorders, with a specific emphasis on primary immunodeficiencies and inherited metabolic diseases. The company specializes in developing innovative therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for the precise and effective insertion of therapeutic genes into blood cells, providing patients with a range of tailored treatment options suitable for their unique conditions. Genespire's mission is to transform the lives of patients affected by severe genetic diseases through cutting-edge therapeutic solutions.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective, safe, and disease-modifying treatment options. Hoba Therapeutics aims to offer relief and prevention for chronic pain and hearing loss, addressing significant medical needs for patients suffering from these conditions.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

D-Orbit S.r.l. is an Italian New Space company founded in 2011 and headquartered in Sesto Fiorentino, Italy. The company specializes in providing solutions for satellite design, development, launch, commissioning, and decommissioning, with a focus on enabling the safe disposal of artificial satellites to mitigate space debris. D-Orbit offers a range of services, including last-mile delivery of satellites, orbital transportation, and space logistics, aimed at optimizing operations both in orbit and on the ground. By streamlining all phases of a satellite mission, D-Orbit enhances spacecraft design, reliability, and resource utilization while reducing operational costs. The company operates with a commitment to social benefit and environmental sustainability, catering to the needs of satellite owners and operators in a rapidly evolving space marketplace. With approximately 35 employees, D-Orbit also has subsidiaries in Washington, DC, and Lisbon, Portugal.

Easy Rain i.S.p.A. is an Italian company founded in 2013, based in Milan, that specializes in enhancing vehicle safety through innovative technology. It has developed a patented active safety system that addresses the hydroplaning phenomenon, which occurs when vehicles lose traction on wet roads due to a layer of water. This issue contributes to millions of accidents annually and poses significant challenges for autonomous driving technologies. Easy Rain’s system prevents excessive water from contacting the tires, thereby improving traction and overall vehicle performance in wet conditions. The company holds extensive patent coverage for its technology and offers solutions that can integrate with remote detection and vision systems to further enhance safety and efficiency for both conventional and electric vehicles.

Alia Therapeutics focuses on developing advanced gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools to target and correct inborn genetic errors directly within patients' cells. By utilizing these unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their source, providing healthcare professionals with the means to modify genomes effectively. Additionally, the company emphasizes safe and efficient delivery mechanisms to ensure the targeted treatment of affected cells.

Sibylla Biotech S.R.L. is an Italian company focused on advancing rational drug design in the pharmaceutical sector. The company specializes in the research, development, and production of innovative therapeutic solutions, particularly through the creation of small molecule folding interfering degraders (FIDs) that target a variety of therapeutic areas. Additionally, Sibylla Biotech provides consultancy services in biotechnology and drug development. The company utilizes patent-based software that applies advanced algorithms and drug design protocols, enabling efficient drug discovery by optimizing reaction paths and streamlining data processes. This approach aims to enhance the rationalization of drug discovery efforts, ultimately contributing to the treatment of challenging medical conditions.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

CYSEC is a startup focused on advancing Confidential Computing solutions that protect data throughout its lifecycle—at rest, in motion, and in use. The company has developed a cloud-based data security software that operates through a physical enterprise-grade server appliance, ensuring the integrity and confidentiality of data stored in the cloud. Their flagship product, the ARCA solution, is gaining popularity in the market for its effectiveness in safeguarding assets. By enabling businesses to innovate in the realm of confidential computing, CYSEC aims to provide robust cybersecurity systems applicable across various sectors.

Cellply is a life-science company dedicated to advancing personalized cancer treatment through the development of innovative analytical tools. The company focuses on creating next-generation diagnostic platforms that enable deep characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics. By utilizing proprietary microfluidic technologies and Co-Culture Array technology, Cellply offers highly automated analytical instruments that combine AI-powered image and data analytics. This approach allows for the precise definition of immune system functions at the single-cell level, facilitating the monitoring of clinical responses to treatments. By automating quality control and supporting research and development processes, Cellply aims to enhance the understanding and effectiveness of novel cancer therapies, ultimately improving patient outcomes.

Cortilia is an online grocery delivery service based in Milan, Italy, that connects consumers directly with local farmers. Founded in 2011, the company focuses on providing fresh, artisanal, and seasonal products while promoting the local economy. By aggregating farmers in virtual markets, Cortilia minimizes waste and ensures that customers receive high-quality goods delivered to their door within a few hours. This sustainable approach allows consumers to easily access farm and dairy products, enhancing the overall shopping experience while supporting regional agriculture.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Expert.ai is a developer of enterprise natural language processing technologies that focuses on transforming language-intensive processes into actionable insights. The company's platform combines symbolic human-like understanding with machine learning, enabling organizations to enhance decision-making and streamline operations. Expert.ai offers a range of solutions, including Cogito Discover, which utilizes artificial intelligence for analytics, extraction, and categorization of text across various formats, thus facilitating automation. Additionally, the Clinical Research Navigator assists biomedical clients in advancing research into therapies for infectious diseases. The company provides its services through on-premise, private, and public cloud offerings, catering to diverse industries such as insurance, banking, publishing, defense, and life sciences.

D-Orbit S.r.l. is an Italian New Space company founded in 2011 and headquartered in Sesto Fiorentino, Italy. The company specializes in providing solutions for satellite design, development, launch, commissioning, and decommissioning, with a focus on enabling the safe disposal of artificial satellites to mitigate space debris. D-Orbit offers a range of services, including last-mile delivery of satellites, orbital transportation, and space logistics, aimed at optimizing operations both in orbit and on the ground. By streamlining all phases of a satellite mission, D-Orbit enhances spacecraft design, reliability, and resource utilization while reducing operational costs. The company operates with a commitment to social benefit and environmental sustainability, catering to the needs of satellite owners and operators in a rapidly evolving space marketplace. With approximately 35 employees, D-Orbit also has subsidiaries in Washington, DC, and Lisbon, Portugal.

D-Orbit S.r.l. is an Italian New Space company founded in 2011 and headquartered in Sesto Fiorentino, Italy. The company specializes in providing solutions for satellite design, development, launch, commissioning, and decommissioning, with a focus on enabling the safe disposal of artificial satellites to mitigate space debris. D-Orbit offers a range of services, including last-mile delivery of satellites, orbital transportation, and space logistics, aimed at optimizing operations both in orbit and on the ground. By streamlining all phases of a satellite mission, D-Orbit enhances spacecraft design, reliability, and resource utilization while reducing operational costs. The company operates with a commitment to social benefit and environmental sustainability, catering to the needs of satellite owners and operators in a rapidly evolving space marketplace. With approximately 35 employees, D-Orbit also has subsidiaries in Washington, DC, and Lisbon, Portugal.

Intrepida Bio, Inc. is a biotechnology company focused on developing innovative cancer therapies by targeting the body's innate immune system. Incorporated in 2016 and based in San Diego, California, the company aims to create medicines that modulate innate immunity to combat cancer and other diseases. Utilizing proprietary monoclonal antibodies, Intrepida Bio works on blocking novel targets, specifically BAG3 and its receptor IFITM-2, to disrupt the tumor-supportive environment. Through this approach, the company seeks to provide patients with effective treatment options that may improve outcomes in cancer care.

Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

Cortilia is an online grocery delivery service based in Milan, Italy, that connects consumers directly with local farmers. Founded in 2011, the company focuses on providing fresh, artisanal, and seasonal products while promoting the local economy. By aggregating farmers in virtual markets, Cortilia minimizes waste and ensures that customers receive high-quality goods delivered to their door within a few hours. This sustainable approach allows consumers to easily access farm and dairy products, enhancing the overall shopping experience while supporting regional agriculture.

BiovelocITA is a business accelerator focused on enhancing the Italian biotechnology sector by supporting early-stage companies. Co-founded by Sofinnova Partners, a prominent entity in the Italian biotech landscape, BiovelocITA leverages a network of top-tier scientists, entrepreneurs, and investors to facilitate the development of innovative ventures. The organization offers comprehensive acceleration services, including mentorship, workspace, and initial funding, aimed at helping startups formulate viable business plans and achieve success in the competitive biotech market. By fostering collaboration among key stakeholders, BiovelocITA plays a crucial role in positioning Italy as a leading player in the European biotechnology arena.

UltraSoC Technologies is an independent provider of system-on-chip (SoC) infrastructure, facilitating the rapid development of embedded systems utilizing advanced SoC devices. Headquartered in Cambridge, with research and development labs in Colchester, the company specializes in on-chip analytics that enhance debugging and optimization processes. Its innovative infrastructure integrates built-in intelligence to continuously monitor and respond to real-world behavior, allowing designers to efficiently create and refine SoCs while reducing costs. By focusing on these capabilities, UltraSoC supports the evolving needs of embedded system developers.

MainStreaming specializes in advanced video streaming technology that enables efficient and high-quality delivery of live and on-demand content. The company utilizes EDGE networks to provide broadcast-grade live video services, catering to some of the largest live streaming operations. Its solutions include an API library for seamless integration across multiple devices, enabling broadcasters to track content performance and audience engagement effectively. MainStreaming addresses the challenges of streaming to millions of simultaneous users by optimizing the delivery process, mitigating congestion, and ensuring secure and reliable viewing experiences. Through its innovative approach, MainStreaming enhances the overall quality of service and maximizes return on investment for its clients in the media sector.

Sweetguest s.r.l., founded in 2016 and based in Milan, Italy, specializes in providing comprehensive management services for short-term rental properties. The company has developed a mobile application that streamlines the reservation process and offers a full range of services to both property owners and their guests. Sweetguest manages all aspects of short-term rentals, including reservations, check-ins, check-outs, laundry, and cleaning. By handling these tasks, Sweetguest enables property owners to maximize their earnings while saving time and effort, ensuring a high-quality experience for everyone involved.

Talent Garden is a leading digital skills academy based in Europe, founded in Italy in 2011. It aims to empower individuals and organizations by providing the knowledge, resources, and spaces necessary for thriving within the innovation ecosystem. The company offers a variety of learning experiences, including online, offline, and hybrid courses, as well as corporate programs and events. Talent Garden operates a network of coworking campuses that fosters a vibrant community of over 45,000 professionals in the digital and tech sectors. Its mission focuses on closing the digital skills gap, having successfully trained more than 25,000 individuals in areas such as digital design, marketing, product management, and cybersecurity. By collaborating with major partners, Talent Garden delivers tailored corporate education programs to promote digital transformation. Its campuses, open 24 hours a day, are designed to facilitate collaboration and provide professionals with a supportive environment to thrive and innovate.

The Data Appeal Company, established in 2014, specializes in AI-driven data analysis and visualization. Headquartered in Florence, Italy, with offices across Europe, the company collects and interprets geographical data, online feedback, customer behaviors, and trends. Its core products, Travel Appeal and Data Appeal Studio, empower businesses to understand and enhance customer experiences through real-time insights, predictive analysis, and semantic understanding. The company's mission is to democratize data usage, making it accessible and understandable for informed decision-making.

Bendit is a medical company focused on the development and manufacturing of innovative catheters that utilize a unique bending technology, allowing for enhanced steering capabilities in both micro diameter and traditional catheter designs. The company specializes in creating microcatheter devices that facilitate optimal navigation within the body, particularly in challenging anatomical areas. Bendit's products are designed to improve procedural efficiency by enabling healthcare professionals to reach target sites with fewer tools, thereby reducing risks and increasing the likelihood of successful outcomes. The organization is a joint venture comprising three experienced groups that bring expertise in production, quality and regulation, and medical development.

Easy Rain i.S.p.A. is an Italian company founded in 2013, based in Milan, that specializes in enhancing vehicle safety through innovative technology. It has developed a patented active safety system that addresses the hydroplaning phenomenon, which occurs when vehicles lose traction on wet roads due to a layer of water. This issue contributes to millions of accidents annually and poses significant challenges for autonomous driving technologies. Easy Rain’s system prevents excessive water from contacting the tires, thereby improving traction and overall vehicle performance in wet conditions. The company holds extensive patent coverage for its technology and offers solutions that can integrate with remote detection and vision systems to further enhance safety and efficiency for both conventional and electric vehicles.

Bendit is a medical company focused on the development and manufacturing of innovative catheters that utilize a unique bending technology, allowing for enhanced steering capabilities in both micro diameter and traditional catheter designs. The company specializes in creating microcatheter devices that facilitate optimal navigation within the body, particularly in challenging anatomical areas. Bendit's products are designed to improve procedural efficiency by enabling healthcare professionals to reach target sites with fewer tools, thereby reducing risks and increasing the likelihood of successful outcomes. The organization is a joint venture comprising three experienced groups that bring expertise in production, quality and regulation, and medical development.

UltraSoC Technologies is an independent provider of system-on-chip (SoC) infrastructure, facilitating the rapid development of embedded systems utilizing advanced SoC devices. Headquartered in Cambridge, with research and development labs in Colchester, the company specializes in on-chip analytics that enhance debugging and optimization processes. Its innovative infrastructure integrates built-in intelligence to continuously monitor and respond to real-world behavior, allowing designers to efficiently create and refine SoCs while reducing costs. By focusing on these capabilities, UltraSoC supports the evolving needs of embedded system developers.

Directa Plus S.p.A. is a nanotechnology company based in Lomazzo, Italy, founded in 2005, that specializes in the production and supply of graphene-based products for both industrial and commercial applications. The company operates through various segments, including Textile, Environmental, and Others, and offers its products under the G+ brand name. Directa Plus's innovative solutions are utilized in a wide range of applications, such as elastomers, smart textiles, polymer nanocomposites, wastewater treatment, and 3D printing. The company has developed advanced manufacturing processes to create high-quality engineered graphene products, with a significant portion of its revenue generated from the environmental segment, which includes applications in oil-spill recovery and water treatment.

Cellply is a life-science company dedicated to advancing personalized cancer treatment through the development of innovative analytical tools. The company focuses on creating next-generation diagnostic platforms that enable deep characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics. By utilizing proprietary microfluidic technologies and Co-Culture Array technology, Cellply offers highly automated analytical instruments that combine AI-powered image and data analytics. This approach allows for the precise definition of immune system functions at the single-cell level, facilitating the monitoring of clinical responses to treatments. By automating quality control and supporting research and development processes, Cellply aims to enhance the understanding and effectiveness of novel cancer therapies, ultimately improving patient outcomes.